Rodent Models of Diabetes

Unique collection of highly translatable models of diabetes

cvmd-magnifyglass.png

"CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease.

Leveraging our industry expertise, CrownBio's global resources help customers answer the most challenging questions about human biology. We begin with the end insight to help you achieve your goals"

Dr Jean-Pierre Wery
CEO, Crown Bioscience Inc.

Conventional and Unique, Proprietary T2D Models

In vivo measurement of glucose and insulin levels are the gold standard for testing your antidiabetic compound efficacy. At CrownBio we can assess the level of circulating sugar or insulin in rodent studies via:

  • Single point measurements via glucometer
  • Continuous telemetry monitoring
  • Glucose and insulin tolerance tests
  • ELISA based assays for insulin determination
  • Glucose clamp tests to quantify insulin resistance.

At CrownBio we understand the need to maintain consistency with historical study data, therefore we can run your study with any commercially available rat or mouse model including rodent models of Type 2 diabetes (T2D) with monogenic mutations:

  • ZDF and ZSF-1 rats
  • db/db and ob/ob mice

Our CardioVascular and Metabolic Disease (CVMD) Translational Technology Platform also provides our highly translatable, proprietary models of T2D:

The FATZO mouse and ZDSD rat are polygenic models of dysmetabolism, spontaneously developing metabolic syndrome, obesity, and diabetes, which more closely mimic the human condition than models with leptin/leptin receptor mutations. Both models respond to antidiabetic treatments, providing highly translatable models for efficacy evaluations.

The FATZO Mouse and ZDSD Rat vs Conventional Type 2 Diabetes Models

Features Fatzo DIO ob/ob db/db
Genetics of the disease Polygenic Polygenic, diet-induced Monogenic, relies on leptin mutation Monogenic, relies on leptin mutation
Weight gain Rapid Rapid Rapid Rapid
Obesity/adiposity Moderate (30%) Moderate (30%) Severe (>40%) Moderate (>30%)
Insulin resistance Rapid Rapid, diet-induced Rapid Rapid
Glucose intolerance High Low High High
Hyperglycemia Moderate Minimal Mild, variable Severe
Hyperlipidemia Moderate Minimal HDL only HDL only
features ZDSD ZDF Zucker DIO rat
Leptin pathway Intact Leprfa, defective Leprfa, defective Intact
Obesity Yes Yes Yes Yes
Insulin resistance Yes Yes Yes Yes
Glucose intolerance Yes Yes Yes Yes
Dyslipidemia Yes Yes Yes Yes
Hypertension Yes No No ?
Hyperglycemia/overt diabetes Yes, from 19 weeks Yes, from 8-11 weeks No No
Beta cell failure Late Early No No
Comordibities Many Some No No
Translational +++++ ++ + +

Male FATZO mice become hyperglycemic at 14 weeks of age, and also develop insulin resistance at an early age.

The ZDSD rat progresses through T2D similarly to humans, with a bona fide prediabetic state occurring at 8-16 weeks of age. The model develops overt diabetes from 16 weeks of age and diabetic complications from 24 weeks of age.

Industry Standard Models of T1D...

We also provide models of Type 1 diabetes such as:

  • Streptozotocin (STZ) induced diabetic rat and mouse models
  • Spontaneously occurring disease models: NOD mice, the BB rat, NRG-Akita mouse with immune deficiency

At CrownBio we also routinely run a variety of in vitro assays including the evaluation of glucose stimulated insulin secretion on isolated primary islets from various rodent models.

Contact us today to discuss your diabetes project needs and experience the value of our expert translational service.

PRECLINOMICS